Bayer AG NA (BAYN) - Total Assets
Based on the latest financial reports, Bayer AG NA (BAYN) holds total assets worth €104.21 Billion EUR as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Bayer AG NA - Total Assets Trend (1998–2024)
This chart illustrates how Bayer AG NA's total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Bayer AG NA - Asset Composition Analysis
Current Asset Composition (December 2024)
Bayer AG NA's total assets of €104.21 Billion consist of 31.1% current assets and 68.9% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €6.19 Billion | 5.6% |
| Accounts Receivable | €8.97 Billion | 8.1% |
| Inventory | €13.47 Billion | 12.2% |
| Property, Plant & Equipment | €13.46 Billion | 12.1% |
| Intangible Assets | €18.43 Billion | 16.6% |
| Goodwill | €30.02 Billion | 27.1% |
Asset Composition Trend (1998–2024)
This chart illustrates how Bayer AG NA's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Bayer AG NA's current assets represent 31.1% of total assets in 2024, a decrease from 50.2% in 1998.
- Cash Position: Cash and equivalents constituted 5.6% of total assets in 2024, up from 0.0% in 1998.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 43.0% of total assets, an increase from 24.0% in 1998.
- Asset Diversification: The largest asset category is goodwill at 27.1% of total assets.
Bayer AG NA Competitors by Total Assets
Key competitors of Bayer AG NA based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
AstraZeneca PLC
NASDAQ:AZN
|
USA | $114.07 Billion |
|
Pfizer Inc
NYSE:PFE
|
USA | $208.73 Billion |
|
Novartis AG
SW:NOVN
|
Switzerland | CHF115.49 Billion |
|
Zhejiang Int'L Group Co Ltd
SHE:000411
|
China | CN¥17.31 Billion |
|
Zhejiang Zhenyuan Share Co Ltd
SHE:000705
|
China | CN¥3.03 Billion |
|
Hunan Jingfeng Pharmaceutical
SHE:000908
|
China | CN¥877.99 Million |
|
Hubei Guangji Pharmaceutical Co Ltd
SHE:000952
|
China | CN¥2.58 Billion |
|
Zhejiang Haisen Pharmaceutical Co. Ltd. A
SHE:001367
|
China | CN¥1.52 Billion |
Bayer AG NA - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.14 | 1.32 | 0.97 |
| Quick Ratio | 0.71 | 0.81 | 0.67 |
| Cash Ratio | 0.20 | 0.18 | 0.00 |
| Working Capital | €3.92 Billion | €8.08 Billion | €-1.07 Billion |
Bayer AG NA - Advanced Valuation Insights
This section examines the relationship between Bayer AG NA's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.53 |
| Latest Market Cap to Assets Ratio | 0.41 |
| Asset Growth Rate (YoY) | -4.7% |
| Total Assets | €110.85 Billion |
| Market Capitalization | $45.18 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Bayer AG NA's assets below their book value (0.41x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Bayer AG NA's assets decreased by 4.7% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Bayer AG NA (1998–2024)
The table below shows the annual total assets of Bayer AG NA from 1998 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | €110.85 Billion | -4.65% |
| 2023-12-31 | €116.26 Billion | -6.90% |
| 2022-12-31 | €124.88 Billion | +3.86% |
| 2021-12-31 | €120.24 Billion | +2.73% |
| 2020-12-31 | €117.05 Billion | -7.30% |
| 2019-12-31 | €126.26 Billion | -0.02% |
| 2018-12-31 | €126.28 Billion | +68.18% |
| 2017-12-31 | €75.09 Billion | -8.70% |
| 2016-12-31 | €82.24 Billion | +11.26% |
| 2015-12-31 | €73.92 Billion | +5.24% |
| 2014-12-31 | €70.23 Billion | +36.86% |
| 2013-12-31 | €51.32 Billion | -0.04% |
| 2012-12-31 | €51.34 Billion | -2.71% |
| 2011-12-31 | €52.77 Billion | +2.44% |
| 2010-12-31 | €51.51 Billion | +0.91% |
| 2009-12-31 | €51.04 Billion | -2.80% |
| 2008-12-31 | €52.51 Billion | +2.21% |
| 2007-12-31 | €51.38 Billion | -8.07% |
| 2006-12-31 | €55.89 Billion | +52.31% |
| 2005-12-31 | €36.69 Billion | -2.86% |
| 2004-12-31 | €37.78 Billion | +1.06% |
| 2003-12-31 | €37.38 Billion | -10.42% |
| 2002-12-31 | €41.73 Billion | +12.47% |
| 2001-12-31 | €37.10 Billion | +1.51% |
| 2000-12-31 | €36.55 Billion | +16.86% |
| 1999-12-31 | €31.28 Billion | +6.47% |
| 1998-12-31 | €29.38 Billion | -- |
About Bayer AG NA
Bayer Aktiengesellschaft operates as a life science company worldwide. The company operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment provides prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast age… Read more